May 25, 2022

Incident conditions that may be attributable to COVID-19 are common among adult COVID-19 survivors, according to research published in the May 24 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Lara Bull-Otterson, Ph.D., from the CDC COVID-19 Emergency Response Team, and colleagues used electronic health record data...

Among patients with an acute heart failure exacerbation, treatment with colchicine for a gout flare is associated with significantly lower in-hospital mortality, according to a study published in Clinical Cardiology. Mary E. Roth, Pharm.D., from the University of Virginia Health in Charlottesville, and colleagues used data for 1,047 patients hospitalized with acute heart failure (March...

Recommended erythropoietin-stimulating agent dosing changes for anemia care in adults undergoing hemodialysis led to lower erythropoietin-stimulating agent use and lower hemoglobin levels, according to a study published in the Clinical Journal of the American Society of Nephrology. Haesuk Park, Ph.D., from the University of Florida in Gainesville, and colleagues examined anemia care and clinical outcomes...

A novel intervention targeting appetitive traits may be an effective option for adult weight loss, according to a study published in JAMA Network Open. Kerri N. Boutelle, Ph.D., from the University of California in San Diego, and colleagues randomly assigned 271 adults (aged 18 to 65 years; body mass index [BMI] of 25 to 45...

The medical community needs new treatments that can lower the chance of COVID-19 worsening in patients. One emerging, promising treatment is molnupiravir—an oral antiviral. To evaluate the safety and efficacy of molnupiravir, researchers for the MOVe-OUT Study Group conducted a phase 3, double-blind, randomized, placebo-controlled trial. Study participants began treatment with molnupiravir 5 days after...